GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Cash, Cash Equivalents, Marketable Securities

Millendo Therapeutics (Millendo Therapeutics) Cash, Cash Equivalents, Marketable Securities : $27.24 Mil (As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Millendo Therapeutics Cash, Cash Equivalents, Marketable Securities?

Millendo Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2020 ($43.21 Mil) to Dec. 2020 ($38.17 Mil) but then stayed the same from Dec. 2020 ($38.17 Mil) to Mar. 2021 ($27.24 Mil).

Millendo Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2018 ($77.67 Mil) to Dec. 2019 ($62.48 Mil) and declined from Dec. 2019 ($62.48 Mil) to Dec. 2020 ($38.17 Mil).


Millendo Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Millendo Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Millendo Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Millendo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.39 67.20 77.67 62.48 38.17

Millendo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.01 50.31 43.21 38.17 27.24

Millendo Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Millendo Therapeutics  (NAS:MLND) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Millendo Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Millendo Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Millendo Therapeutics (Millendo Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
110 Miller Avenue, Suite 100, Ann Arbor, MI, USA, 48104
Millendo Therapeutics Inc is a biopharmaceutical company.
Executives
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Howe John P Md director C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Geoffrey Nichol director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Ryan Zeidan officer: Chief Development Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Julia C. Owens director, officer: President and CEO C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Tamara L Joseph officer: General Counsel and Secretary 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Arcudi Iii Louis J officer: Chief Financial Officer C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139
Randall W Whitcomb director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Jeffery M. Brinza officer: Sec., CAO and General Counsel C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451